Shanrong Biotechnology Corp.
Other OTCTotal Valuation
Shanrong Biotechnology Corp. carries a market capitalization of 298.00, placing it among publicly traded companies globally. Its enterprise value stands at 1.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 298.00 |
| Enterprise Value | 1.88M |
Share Statistics
Shanrong Biotechnology Corp. currently has 348,938.00 shares outstanding.
| Shares Outstanding | 348,938.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 1.42 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 443.34 |
Financial Position
Shanrong Biotechnology Corp. maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -47.90, indicating conservative leverage, while an interest coverage ratio of -18.10 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.03 |
| Quick Ratio | 0.03 |
| Debt / Equity | -47.90 |
| Debt / EBITDA | -0.39 |
| Interest Coverage | -18.10 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -5,291.72 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 25.71 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Shanrong Biotechnology Corp.'s stock has declined approximately -99.96429% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.09.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.96429% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.09 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shanrong Biotechnology Corp. generated 1.32M in revenue and converted that into -5.08M in net income, yielding earnings per share of -15.88. EBITDA reached -4.89M, while operating income came in at -4.93M.
| Revenue | 1.32M |
| Gross Profit | 1.32M |
| Operating Income | -4.93M |
| Pretax Income | -5.08M |
| Net Income | -5.08M |
| EBITDA | -4.89M |
| EBIT | -4.93M |
| Earnings Per Share (EPS) | -15.88 |
Balance Sheet
Shanrong Biotechnology Corp. holds 30,867.00 in cash and equivalents against 1.91M in total debt, resulting in a net debt position of 1.87M. Total book value stands at -10.39M, with working capital of -3.92M providing operational flexibility.
| Cash & Cash Equivalents | 30,867.00 |
| Total Debt | 1.91M |
| Net Debt | 1.87M |
| Equity (Book Value) | -10.39M |
| Book Value Per Share | -32.47 |
| Working Capital | -3.92M |
Cash Flow
Shanrong Biotechnology Corp. produced -787,420.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -787,420.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -787,420.00 |
| FCF Per Share | -2.46 |
Margins
Shanrong Biotechnology Corp. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -371.83 and net profit margin of -383.32 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -371.83 |
| Pretax Margin | -383.32 |
| Profit Margin | -383.32 |
| EBITDA Margin | -369.14 |
Stock Splits
Shanrong Biotechnology Corp.'s most recent stock split took place on September 25, 2017 with a 100:1 split ratio.
| Last Split Date | 9/25/2017 |
| Split Ratio | 100:1 |
Scores
Shanrong Biotechnology Corp. posts an Altman Z-Score of -179.63, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -179.63 |